The single-arm, non-comparative design of this study makes no conclusions based on the secondary objective of the anti-tumor activity on tumor recurrence. Non – muscle – invasive bladder cancer is highly heterogeneous due to the variability in tumor and histological grading, risk factors such as tumor size and multiplicity, number of employed from recurrence and the significant variety of different post – resection treatment regimens, comparison of comparison of tumor recurrence data in clinical studies difficult. Without proper controls and an appropriate balance of risk factors may not be reliable conclusions drawn from these descriptive data only. Bladder cancer.
This cohort has now. Maintenance treatment period of the study with the the same phase of chemo treatment every three months until the patient reaches two years of study , or a tumor recurrence Based on the filing date of the last patient can overdose last until September 2009.. Phase I / IIa Clinical Trial Phase chemotherapy detailsThe trial enrolled 27 patients between the four sites. Each patient received fixed doses of 40 mg of and doses of mitomycin rHuPH20 after assignment to one of five pre-defined dose groups. All 15 patients in cohorts one through four have induction therapy consisting of six weekly intravesical instillations chemo phase with rHuPH20 doses of 20,000 to 400,000 units, each complete. The fifth cohort consisted at 12 patients who received the highest weekly dose of 800,000 units of rHuPH20 during induction.Surveyed Researchers 40 storage motorists in 27 countries, obtain information about injuries, the physical requirements of and other factors participated to stock car racing. In addition, she approached the drivers about your physical training programs. That majority of drivers was considered regionally or nationally.